Bridging the Gap Between CBD Science and Regulation
In 2018, CBD sales in the United States were estimated at $534 million, according to the Hemp Business Journal. USA projections in 2025 are expected to reach an estimated $25 Billion. To many, CBD offers a variety of benefits when ingested, inhaled, or applied topically – with product marketing and advertising claims similarly ranging from calming effects to pain relief. Asa Waldstein joins the Atlantia team to discuss how to use clinical data for marketing purposes to overcome regulatory hurdles that many CBD companies are encountering when commercializing their innovations.
Duration: 42 mins
![A-female-doctor-sits-at-her-desk-and-chats-to-an-elderly-female-patient-while-looking-at-her-test-results A-female-doctor-sits-at-her-desk-and-chats-to-an-elderly-female-patient-while-looking-at-her-test-results](https://atlantiaclinicaltrials.com/hs-fs/hubfs/WEBSITE%20-%20LATEST%20IMAGES%20FEB%202024/A-female-doctor-sits-at-her-desk-and-chats-to-an-elderly-female-patient-while-looking-at-her-test-results.jpg?width=600&height=600&name=A-female-doctor-sits-at-her-desk-and-chats-to-an-elderly-female-patient-while-looking-at-her-test-results.jpg)
Webinar
Speakers
![Ted Dinan](https://atlantiaclinicaltrials.com/hubfs/Atlantia_Clinical_Trials_November_2023/Images/649c44339b81d5725fcd95da_ted-dinan.jpg)
Ted Dinan
Top cited scientist in the gut-brain axis, over 400 papers published in neurobiology.
Medical Director
Atlantia Clinical Trials